Irish journal of medical science
-
Review Meta Analysis
The prevalence of premenstrual dysphoric disorder among adolescents in Ethiopia: a systematic review and meta-analysis.
The rates of prevalence of premenstrual dysphoric disorder (PMDD) in Ethiopia were high and inconsistent across studies. However, there was no previous systematic reviews and meta-analysis conducted on this topic. Therefore, this review aimed to systematically review previous studies on the topic and summarize the prevalence of PMDD among students in Ethiopia and formulate recommendations for future clinical services. ⋯ Further, the pooled estimated prevalence of premenstrual dysphoric disorder was ranging from 51.2 to 57.2% in leave-one-out sensitivity analysis, suggesting that the removal of one study did not affect the overall prevalence estimate. The pooled estimated prevalence of premenstrual dysphoric disorder among female students in Ethiopia was high. Early screening and appropriate interventions at primary healthcare settings are warranted.
-
Review Meta Analysis
The prevalence of premenstrual dysphoric disorder among adolescents in Ethiopia: a systematic review and meta-analysis.
The rates of prevalence of premenstrual dysphoric disorder (PMDD) in Ethiopia were high and inconsistent across studies. However, there was no previous systematic reviews and meta-analysis conducted on this topic. Therefore, this review aimed to systematically review previous studies on the topic and summarize the prevalence of PMDD among students in Ethiopia and formulate recommendations for future clinical services. ⋯ Further, the pooled estimated prevalence of premenstrual dysphoric disorder was ranging from 51.2 to 57.2% in leave-one-out sensitivity analysis, suggesting that the removal of one study did not affect the overall prevalence estimate. The pooled estimated prevalence of premenstrual dysphoric disorder among female students in Ethiopia was high. Early screening and appropriate interventions at primary healthcare settings are warranted.
-
To assess for changes in trends of GP chest radiograph reporting over a 10-year period and to assess if there has been a change in recommendations for follow-up. ⋯ Along with the increase in the quantity of GP-referred chest radiographs over the past 10 years, suggestions for follow-up have increased, particularly for nodule surveillance. Reasons for this increase may include lack of availability of CT to GPs for lung cancer screening, insensitivity of plain radiographs to early cancer detection, and possible fear of litigation for missing lesions, making radiologists more cautious.
-
As the novel coronavirus disease 2019 (COVID-19) continues to spread across countries, the need for innovative measures to provide high-quality patient care and manage its spread has become more imperative. Software-based systems such as medical software applications could provide valuable suggestion on health-related information to physicians towards improving quality of life, especially for outpatients (e.g., elderly, immunosuppressed, pregnant women). ⋯ More importantly, findings present factors that impact adoption of telemedicine. The findings suggest that telemedicine and virtual software are capable of decreasing emergency room visits, safeguarding healthcare resources, and lessening the spread of COVID-19 by remotely treating patients during and after the COVID-19 pandemic.
-
Cancer is a major burden on the healthcare system, and new therapies are needed. Recently, the development of immunotherapies, which aim to boost or use the immune system, or its constituents, as a tool to fight malignant cells, has provided a major new tool in the arsenal of clinicians and has revolutionized the treatment of many cancers. ⋯ The ensuing years have seen two further cellular immunotherapies gain FDA approval: tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta). This review will give an overview of the principles of immunotherapies before focusing on the major forms of cellular immunotherapies individually, T cell-based, natural killer (NK) cell-based and dendritic cell (DC)-based, as well as detailing some of the clinical trials relevant to each therapy.